仁度生物(688193) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 177.35 million, an increase of 7.87% compared to the previous year[4] - The net profit attributable to the parent company was a loss of RMB 7.38 million, a decrease of 189.32% year-on-year[4] - Basic earnings per share decreased by 185.71% to RMB -0.18[4] - The company faced a significant decline in operating profit, down 362.40% year-on-year[7] - The total profit decreased by 413.21% compared to the previous year[7] Assets and Equity - The total assets at the end of the reporting period were RMB 994.94 million, a decrease of 5.67% from the beginning of the period[6] - The equity attributable to the parent company was RMB 912.31 million, down 5.24% from the beginning of the period[6] Performance Decline Factors - The company attributed the decline in performance to credit impairment losses and reduced government subsidies[6][7] Strategic Focus - The company is focusing on market expansion and key product promotion to counteract macroeconomic challenges[6] Caution for Investors - Investors are advised to note that the financial data is preliminary and subject to audit, emphasizing the need for caution[9]